The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

called the FDA’s approval a "promising advancement for the millions of people who suffer from this condition." "Zepbound promotes weight loss and has been shown to reduce apnea events." ...

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...

which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, in November 2023. Although the new FDA green light doesn’t expand the ...

The the US Food and Drug Administration (FDA) has approved the first medication ... “Zepbound promotes weight loss and has been shown to reduce apnea events,” Troxel noted.